Please try another search
For the three months ended 31 March 2019, Peloton Therapeutics Inc revenues was not reported. Net loss increased 26% to $9.5M. Higher net loss reflects Research and development - Balancin increase of 16% to $7.5M (expense), General and administrative increase of 63% to $1.8M (expense), Stock-based Compensation in SGA increase from $75K to $288K (expense).
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Mar 31, 2018 |
---|---|---|---|
Total Revenue | 0 | 0 | 0 |
Gross Profit | |||
Operating Income | -9.78 | -37.09 | -7.75 |
Net Income | -9.53 | -36.07 | -7.59 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Mar 31, 2018 |
---|---|---|---|
Total Assets | 175.63 | ||
Total Liabilities | 10.55 | ||
Total Equity | 165.07 |
Period Ending: | Mar 31, 2019 | Dec 31, 2018 | Mar 31, 2018 |
---|---|---|---|
Period Length: | 3 Months | 12 Months | 3 Months |
Cash From Operating Activities | -10.27 | -33.22 | -9.45 |
Cash From Investing Activities | -0.45 | -0.67 | -0.23 |
Cash From Financing Activities | 150.15 | 18.66 | 0.22 |
Net Change in Cash | 139.43 | -15.23 | -9.46 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review